P-0169 - Neoadjuvant chemoradiation for rectal cancers

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Rectal Cancer
Surgery and/or Radiotherapy of Cancer
Presenter Charu Singh
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors C. Singh1, S. Gupta2
  • 1S.M.S. Medical College and Hospital, Jaipur/IN
  • 2S.M.S. Hospital, Jaipur/IN



The aim of study is to evaluate the efficacy of neoadjuvant chemoradiation in locally advanced and unresectable rectal cancer patients in terms of sphincter preservation, pathological response, and overall survival.


80 patients of carcinoma rectum comprising of resectable, borderline resectable, and unresectable cases were included in the study. All were treated by neoadjuvant chemoradiation with 45-50 Gy conventional fractionation external beam radiotherapy (EBRT) and concurrent oral capecitabine chemotherapy. All the patients were assessed at 6 weeks following completion of chemoradiation by clinical examination and/or CT/MRI scan pelvis for response evaluation. The choice of surgery, either abdominoperineal resection or anterior resection, was made on basis of response.


With a median follow-up of 24 months, the median overall survival was 18 months, all stages combined. The pathological complete response among all stages was 20%. Overall survival among different age groups came out to be significant between resectable and unresectable, as well as between borderline resectable and unresectable cancers. Those who had no luminal obstruction at presentation had a better overall survival compared to others and more pronounced among borderline resectable cases.


The study emphasized upon optimum use of neoadjuvant chemoradiation in locally advanced rectal cancer.